Vitrology was successfully sold in May 2012 to SGS, a Swiss company listed in Geneva with a substantial UK presence. Archangels original investment was made in 2007.
Vitrology is a Biopharmaceutical Contract Research Organisation (CRO). By assisting clients in addressing regulatory concerns around viral safety and other related biosafety issues, it allows them to enter clinical trials or market a licensed biological product.
Vitrology work in close collaboration with clients from the early stages of their new drug discovery and development programs, tailoring advice and extending services to meet the precise requirements of each project. Additionally, Vitrology develops, conducts and validates custom studies, devising innovative testing procedures and addressing the unique test specifications required for novel therapeutics.